Skip to main content
Sun Pharma Advanced Research Company Ltd. logo

Sun Pharma Advanced Research Company Ltd. — Investor Relations & Filings

Ticker · SPARC ISIN · INE232I01014 LEI · 3358001Y3QHHUNROTJ51 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 638 across all filing types
Latest filing 2026-01-17 Regulatory Filings
Country IN India
Listing BSE.NS SPARC

About Sun Pharma Advanced Research Company Ltd.

https://www.sparc.life

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative pharmaceutical products and drug delivery systems. SPARC focuses on creating new chemical entities (NCEs), new biological entities (NBEs), and reformulated products that address significant unmet medical needs. The company utilizes proprietary technology platforms, such as WrapMatrix and Nanotecton, to enhance the efficacy and safety of treatments. Its research pipeline primarily targets therapeutic areas including oncology, neurodegeneration, and ophthalmology. SPARC advances candidates through various stages of clinical trials to provide value-added medicines and novel therapeutic solutions for complex health conditions, leveraging its expertise in formulation and clinical development to improve patient outcomes globally.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) dated January 17, 2026, informing about the publication of a newspaper advertisement regarding an Extraordinary General Meeting (EGM) of the company. It mentions the advertisement was published in Financial Express editions and that the notice convening the EGM was sent electronically to shareholders. The content is an announcement about the publication of the EGM notice and related information, not the actual notice or meeting materials themselves. The document length is 15,000 characters, but the content is primarily an announcement of the advertisement and meeting notice distribution, not the meeting materials or voting results. Therefore, this fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about the EGM notice publication, rather than the actual meeting materials (AGM-R), voting results (DVA), or proxy solicitation (PSI).
2026-01-17 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of an Extraordinary General Meeting (EGM) scheduled for February 9, 2026, issued by Sun Pharma Advanced Research Company Limited. It includes a special resolution proposal for the issue of convertible warrants on a preferential basis to a promoter group member. The notice references compliance with SEBI Listing Regulations, Companies Act 2013, and other regulatory frameworks. The content is focused on the announcement and details of the EGM and the proposed capital raising transaction through preferential allotment of warrants. It does not contain financial statements or management discussion and analysis but is a formal meeting notice with resolutions to be voted on. This fits the category of Proxy Solicitation & Information Statement (PSI), as it is material sent to shareholders to provide information and request votes for the meeting. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement. Therefore, the appropriate classification is PSI with high confidence.
2026-01-16 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (National Stock Exchange of India Ltd. and BSE Limited) informing them about the publication of a newspaper advertisement regarding an Extra Ordinary General Meeting (EGM) of the company. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and mentions that the notice of the EGM and related information have been published in a newspaper and are available on the company's website. The document does not contain any financial data, detailed report content, or voting results. It is essentially an announcement informing the exchanges about the publication of the EGM notice and related information. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories such as AGM Information, Declaration of Voting Results, or Proxy Solicitation.
2026-01-16 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) informing them about the publication of a newspaper advertisement regarding an Extra Ordinary General Meeting (EGM) of the company. It mentions that the notice of the EGM and related information has been published in newspapers and is also available on the company's website. The document does not contain the actual notice or detailed meeting materials but is an announcement about the publication of such notice. The document length is 15,000 characters, but the content is primarily an announcement of the notice publication, not the notice itself or any detailed report. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Report Publication Announcement (RPA) rather than the actual meeting notice or other report types.
2026-01-15 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure from Sun Pharma Advanced Research Company Limited addressed to stock exchanges, referencing SEBI Listing Regulations and SEBI Master Circulars. It announces the board's approval of a preferential issue of convertible warrants to a promoter group member and the formulation of an Employee Stock Option Scheme (ESOP) 2026. It also mentions convening an Extraordinary General Meeting (EGM) for member approval of these matters. The document includes detailed annexures with disclosures about the preferential issue and ESOP scheme, including numbers, pricing, and regulatory compliance. The content is regulatory disclosure about corporate actions related to capital raising and employee stock options, not a financial report or earnings release. It is not an announcement of a report publication but a substantive update on capital/financing activities and corporate governance matters. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2026-01-14 English
Investor Presentation
Call Transcript Classification · 100% confidence The document is a detailed transcript of an investor conference call held by Sun Pharma Advanced Research Company Limited (SPARC) on January 8, 2026, discussing R&D updates, clinical programs, regulatory matters, and strategic plans. It includes a moderator introduction, management presentations, and Q&A format typical of earnings or investor call transcripts. The document references the transcript being attached and available on the company website, and it contains 15,000 characters, indicating a full transcript rather than a brief announcement. The content focuses on pipeline updates, clinical trial progress, regulatory interactions, and strategic outlook, which aligns with the nature of a Call Transcript (CT). There is no indication that this is an earnings release (ER) with only key highlights, nor is it an annual or interim report. It is not a report publication announcement or a regulatory filing. Therefore, the appropriate classification is Call Transcript (CT).
2026-01-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.